Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dendritic Cells in Cancer Immunology and Immunotherapy.
Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, Sarobe P, Inogés S, Díaz de Cerio AL, Santisteban M. Hato L, et al. Among authors: gallego perez larraya j. Cancers (Basel). 2024 Feb 28;16(5):981. doi: 10.3390/cancers16050981. Cancers (Basel). 2024. PMID: 38473341 Free PMC article. Review.
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
Di Stefano AL, Labussiere M, Lombardi G, Eoli M, Bianchessi D, Pasqualetti F, Farina P, Cuzzubbo S, Gallego-Perez-Larraya J, Boisselier B, Ducray F, Cheneau C, Moglia A, Finocchiaro G, Marie Y, Rahimian A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M. Di Stefano AL, et al. J Neurooncol. 2015 Feb;121(3):499-504. doi: 10.1007/s11060-014-1677-x. Epub 2014 Dec 7. J Neurooncol. 2015. PMID: 25488073
Correction: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA, Diez-Valle R, Gállego Pérez-Larraya J, Moreno-Jiménez M, Idoate MÁ, Arbea L, Tejada S, Eulate MRG, Ramos L, Arbizu J, Domínguez P, Aristu JJ. Jablonska PA, et al. PLoS One. 2019 Jul 8;14(7):e0219614. doi: 10.1371/journal.pone.0219614. eCollection 2019. PLoS One. 2019. PMID: 31283793 Free PMC article.
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY. Gállego Pérez-Larraya J, et al. J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27. J Clin Oncol. 2011. PMID: 21709196 Clinical Trial.
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.
Laffaire J, Di Stefano AL, Chinot O, Idbaih A, Gallego Perez-Larraya J, Marie Y, Vintonenko N, Boisselier B, Farina P, Delattre JY, Figarella-Branger D, Honnorat J, Sanson M, Ducray F. Laffaire J, et al. Biomed Res Int. 2014;2014:282815. doi: 10.1155/2014/282815. Epub 2014 Apr 2. Biomed Res Int. 2014. PMID: 24804210 Free PMC article. Clinical Trial.
Detection of IDH1 mutation in the plasma of patients with glioma.
Boisselier B, Gállego Pérez-Larraya J, Rossetto M, Labussière M, Ciccarino P, Marie Y, Delattre JY, Sanson M. Boisselier B, et al. Neurology. 2012 Oct 16;79(16):1693-8. doi: 10.1212/WNL.0b013e31826e9b0a. Epub 2012 Oct 3. Neurology. 2012. PMID: 23035067
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Gállego Pérez-Larraya J, et al. Neuro Oncol. 2012 May;14(5):667-73. doi: 10.1093/neuonc/nos070. Epub 2012 Apr 4. Neuro Oncol. 2012. PMID: 22492961 Free PMC article.
61 results